Navigation Links
GlaxoSmithKline Wins Environmental Stewardship Award
Date:2/24/2011

vestment (eROI) that GSK has achieved from using Nalco's sustainable solutions includes:

  • more than 325,000 cubic meters (85.8 million gallons) of water savings, enough for the annual water needs of nearly 3,400 people,
  • 4.1 million kWh of energy savings, equal to 147 households annual use, and
  • 2,000 metric tonnes of CO2 reduction, equal to more than 83,000 trees.

These environmental improvements also resulted in financial savings for GSK of more than pounds Sterling 1.3 million since 2008.

The award selection committee included Nalco representatives and input from the Water Innovation Alliance (WIA).  

GlaxoSmithKline – one of the world's leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information please visit www.gsk.com.

About Nalco

Nalco is the world's largest sustainability services company focused on industrial water, energy and air applications; delivering significant environmental, social and economic performance benefits to our customers.  We help our customers reduce energy, water and other natural resource consumption, enhance air quality, minimize environmental releases and improve productivity and end products while boosting the bottom line.  Together our comprehensive solutions contribute to the sustainable development of customer operations.  Nalco is a member of the Dow Jones Sustainability Indexes.  More than 12,000 Nalco employees operate in 150 countries supported by a comprehensive network of manufacturing facilities, sales offices and research centers to serve a broad range of end markets.  In 2010, Nalco achieved sales of $4.25 billion.  For more information, visit www.nalco.com
'/>"/>

SOURCE Nalco
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. GlaxoSmithKline 15th Annual IMPACT Awards Seek Philadelphia Area and Camden Healthcare Nonprofits
2. GlaxoSmithKline Applauds North Carolinas Child Advocates
3. A Statement from GlaxoSmithKline Consumer Healthcare on FDA Regulation of Smokeless Tobacco Products
4. Mylan Granted Temporary Restraining Order Against GlaxoSmithKline and Apotex Prohibiting the Supply, Sale and/or Importing of a Generic Version of Paxil CR
5. GlaxoSmithKline CEO Interviewed On Half-Year and Q2 Results
6. GlaxoSmithKline Statement in Response to FDA Advisory Committees Vote on Safety of Avandia® (rosiglitazone)
7. ImaginAb, Inc. and GlaxoSmithKline Establish Collaboration
8. Johnson Controls Secures Global Facilities Management Win With GlaxoSmithKline
9. North Carolina GlaxoSmithKline Foundation Working With Nonprofits to Promote Health, Science and Education Through Ribbon of Hope Grants
10. Cellzome Announces Second Major Strategic Drug Discovery Alliance with GlaxoSmithKline in Inflammatory Disease
11. GlaxoSmithKline Responds to US Senate Committee on Finance Report on Avandia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014 MultiCell Technologies, Inc. (OTC Bulletin ... provisional patent application concerning composition of matter, biological targets, ... tumor cell death.  This patent application ... stranded RNA molecules (VSRNAs) which interfere with the basic ...
(Date:1/15/2014)... , Jan. 15, 2014  According to Millennium Research ... market intelligence, the United States ... device markets will expand moderately through 2022, with ... In particular, increasing interest in drug-eluting beads (DEBs) ...
(Date:1/15/2014)... LAVAL, Quebec , Jan. 15, 2014  Valeant Pharmaceuticals ... VRX) announced that the applicable waiting period under the ... to the previously announced tender offer by its indirect ... the outstanding shares of common stock of Solta Medical, ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
... Presented Along With Updated Phase 1 Colorectal Cancer ... Data at ... CHICAGO, June 1 /PRNewswire-FirstCall/,-- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ... results,from its ongoing randomized Phase 2 clinical trial in patients ...
... Greater Than 50% Response Rate and 100% Disease Control Rate Observed ... Patients with Medullary Thyroid Cancer, ... encouraging new data from an ongoing phase 1 clinical trial of,XL184, ... with advanced malignancies. The maximum tolerated dose (MTD) for,XL184 has been ...
Cached Medicine Technology:Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer 2Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer 3Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer 4Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer 5Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 2Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 3Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 4Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 5Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 6
(Date:4/17/2014)... McCullers, MD, was recently invited to submit a ... Reviews Microbiology , one of the world,s foremost ... disease specialist, and chair of the Department of ... Center, analyzed the epidemiology and microbiology of co-infections ... well as more recent 2009 novel H1N1 pandemic. ...
(Date:4/17/2014)... Doctors who treat patients with a severe ... face an agonizing treatment decision. , The drug ... help relieve shortness of breath. But some patients ... cause potentially fatal complications following transplantation. , "It,s ... medical director of Loyola University Medical Center,s LAM ...
(Date:4/17/2014)... 17, 2014-- Colic affects about one in five infants ... pediatric visits during the first several months after birth. ... was showing promise; however, the April 1, 2014 issue ... Valerie) reported on a study, "Probiotics and Infant Colic," ... reuteri for infant colic did not reduce ...
(Date:4/17/2014)... EcoHealth Alliance, a nonprofit organization that focuses on ... review today examining the current state of knowledge of ... for improved global surveillance strategies to combat the emergence ... Ebola in West Africa that has claimed the lives ... Liberia. According to the World Health Organization (WHO), ...
(Date:4/17/2014)... international research team led by Cesar A. Arias, M.D., ... at Houston (UTHealth) has identified a new superbug that ... report appeared in the April 17 issue of ... new superbug is part of a class of highly-resistant ... MRSA, which is a major cause of hospital and ...
Breaking Medicine News(10 mins):Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:New MRSA superbug emerges in Brazil 2
... , AVENTURA, Fla., Dec. 21 Cinergy ... benefit programs for the consumer market, expressed its concern for the ... this morning. , "While the Senate and House healthcare bills are ... step towards expanding access to affordable health coverage for all Americans," ...
... on edibles that will signal fullness just by chewing ... possible to create foods with hunger-suppressing aromas that would offer ... scientists say. , Researchers have long attempted to develop foods ... until recently, have focused on the effects of food in ...
... powerful results in mice and people, researchers say , ... a protein that may be involved in the development ... to new drugs to fight this growing worldwide scourge. ... inhibiting this pathway worked to block pain associated with ...
... ... schedules have been finalized for the ,second annual Dr. Alec Kessler Memorial High School ... Center., , ... (Vocus) December 21, 2009 -- The teams and the tournament schedules have been finalized for ...
... , BOCA RATON, Fla., Dec. 21 Flipping ... system for children and adults, has teamed up with Fisher ... to the retail value of $10,000 - to the children ... In an effort to make the holidays a bit ...
... , , AARP PENNSYLVANIA KEY VOTE NEWS ALERT , ATTENTION ... on key issues throughout the 111th Congress, and informing its nearly ... these key votes. , HARRISBURG, Pa., Dec. 21 The U.S. ... that will begin to bring needed relief to millions of Americans ...
Cached Medicine News:Health News:Cinergy Health Commentary on Senate Healthcare Vote 2Health News:Diabetes Insight Could Lead to Better Treatments 2Health News:Teams And Tournament Schedule Finalized For The Dr. Alec Kessler Memorial High School Basketball Invitational December 28-30, 2009 2Health News:Teams And Tournament Schedule Finalized For The Dr. Alec Kessler Memorial High School Basketball Invitational December 28-30, 2009 3Health News:Flipping for Phonics(TM) Helps Spread Cheer To Military Families In Fisher Houses(R) This Holiday Season 2Health News:Flipping for Phonics(TM) Helps Spread Cheer To Military Families In Fisher Houses(R) This Holiday Season 3Health News:AARP Applauds Senate for Moving Health Care Reform Forward 2Health News:AARP Applauds Senate for Moving Health Care Reform Forward 3
The UniCel DxI 800 with its exceptional throughput, proven chemiluminescent technology, assay protocols like Access, Access 2, Synchron LXi 725 and load "on-the-fly" capability simplifies and automat...
... The Access immunoassay system ... access benchtop analyzer that ... assays, with panels that ... thyroid, infectious disease, blood ...
...
...
Medicine Products: